Senseonics Holdings, Inc. SENS

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world’s first and only long-term, one-year implantable sens

GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences. Details on the Company’s participation appear below: Lake Street 10th Annual Big Ideas Growth Conference – September 10, 2026 (New York, NY)Management will host o

Sensirion Holding AG (XSWX:SENS) lifts full-year outlook on strong demand across all end markets, despite a 3% decline in reported revenue due to Swiss franc strength.

Strong US growth and record gross margins drive raised guidance, though increased investment costs widen net loss.

Senseonics (SENS) delivered earnings and revenue surprises of -14.55% and +10.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-yearRaising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%Achieved gross margin of approximately 59% during Q2, and raising full-year gross margin guidance to a range of 58% to 61% from 55% to 58% GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technolo

GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will hold a conference call to review the Company’s second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The co

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximately USD 16.8 Billion in 2025 and is expected to reach USD 18.3 Billion in 2026 and is expected to reach around USD 39.4 Billion by 2035, at a CAGR of 8.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Insulet Corporati

The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.

By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.

Analysts have reset their average price target for Senseonics Holdings to about US$13.80, down from around US$18.92, reflecting a roughly 27% cut in the equity value embedded in their models. Recent commentary focuses on how this new target lines up with the current share price, with some firms stressing potential upside if the company executes well and others emphasizing the risks that led them to trim expectations. As you read on, you will see how these shifting targets shape the evolving...